NK 242
Latest Information Update: 14 Feb 2008
At a glance
- Originator Kowa Pharmaceutical
- Class Antineoplastics; Dihydropyridines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Feb 1995 Suspended-Unspecified phase for Cancer in Japan (Unknown route)